(Q37818472)

English

Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists

scientific article published on September 1996

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1 reference

Europe PubMed Central

Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

author name string

D J Campbell

1

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

publication date

1 September 1996

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Clinical and Experimental Pharmacology and Physiology

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

23 Suppl 3

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

S125-31

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Endothelium-dependent mechanical properties of the carotid artery in WKY and SHR. Role of angiotensin converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.1996.TB03073.X

21 January 2018

Identifiers

10.1111/J.1440-1681.1996.TB03073.X

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37818472&oldid=2223346356"